AI Scribe for Hematologists
Built for benign and malignant hematology. Reads CBC differentials by morphology, trends INR and DOAC adherence, captures hydroxyurea titration and BM biopsy notes, and produces a finished SOAP between patients.
Documentation for Every Hematology Visit
From a 15-minute INR check to a 60-minute new sickle cell consult, the workflow mirrors how hematologists actually structure encounters.
Anticoagulation Management
Warfarin INR clinic, DOAC dosing (apixaban 5mg BID, rivaroxaban 20mg daily, dabigatran 150mg BID), AFib stroke prevention, post-VTE management, HAS-BLED scoring.
Sickle Cell Disease
Crisis review, hydroxyurea titration, transfusion needs, iron overload, vaso-occlusive pain plan, exchange transfusion eligibility, hydroxyurea 500mg-2000mg daily dose.
Anemia Workup
MCV-based differential (microcytic, normocytic, macrocytic). Iron studies (ferritin, TIBC, transferrin saturation), B12/folate, retic count, IV iron sucrose infusion plans.
Bleeding Disorders
Von Willebrand disease, hemophilia A/B, ITP, platelet dysfunction. Factor levels, DDAVP response, target trough management, surgical hemostasis planning.
Hereditary Conditions
Thalassemia, hereditary spherocytosis, G6PD deficiency, hereditary hemochromatosis, sickle cell trait counseling, genetic counseling referrals.
BMT Follow-Up
Post-allogeneic and autologous transplant clinic. Engraftment, GVHD grading (acute and chronic), infection prophylaxis, immunosuppression taper, vaccination schedule.
What Makes It Hematology-Specific
These features reflect the parts of a hematology note that consume the most after-clinic charting time.
CBC Interpretation by Morphology
Microcytic vs normocytic vs macrocytic differential, RDW high vs normal, retic-corrected response, MCHC for spherocytes. The system reads the differential and frames the assessment around the most likely diagnosis.
INR and DOAC Dose Tracking
Trend INR across visits with the warfarin dose at each point, time-in-therapeutic-range estimate, and the dose change rationale. For DOACs, captures renal-adjusted dosing (apixaban 2.5mg BID for CrCl <30 with age >=80) and the AFib indication and CHA2DS2-VASc.
Iron Studies and Iron Replacement
Ferritin, TIBC, transferrin saturation, and serum iron together drive the differential between iron deficiency, anemia of chronic disease, and iron overload. Documents oral vs IV iron decision (iron sucrose 200mg IV x 5 doses, ferric carboxymaltose 750mg IV x 1) with the clinical rationale.
Sickle Cell Crisis Capture
Pain crisis history with frequency, location, severity (0-10), home opioid regimen, and ED/admission count over the past year. Captures hydroxyurea dose and HbF response, transfusion frequency for chronic transfusion programs, and chelation status.
Bone Marrow Biopsy Notes
Structured procedure note for BM aspiration and core biopsy. Site (posterior iliac crest), local anesthetic, sedation, sample adequacy, complications, and the bottom-line cellularity and morphology read - all tied to CPT 38220 or 38221.
Bleeding Risk and Stroke Risk Scores
HAS-BLED for anticoagulation bleeding risk. CHA2DS2-VASc for AFib stroke risk. ORBIT for an alternative bleeding score. Each appears in the assessment with the actual numerical score and the clinical decision it supports.
A Day in a Hematology Clinic with PatientNotes
Why the documentation burden is heavy here, and what changes.
A general hematology day is structured around three high-volume encounter types. Anticoagulation visits (warfarin INR clinic, DOAC follow-up) are short individually but dense - the visit centers on bleeding-risk vs stroke-risk vs VTE-recurrence-risk calculus, and the documentation must capture HAS-BLED, CHA2DS2-VASc, INR trend, dose adjustments, and counseling on bleeding red flags. Sickle cell visits track crisis frequency, hydroxyurea titration, HbF response, and chronic transfusion logistics. Anemia workups demand a structured CBC interpretation with iron studies, B12/folate, retic, and a clear MCV-driven differential.
Two features make hematology notes harder than they look: (1) the same lab values (CBC, ferritin, LDH, retic) need different framing depending on the differential, and (2) every visit must restate the indication for therapy and the bleeding-risk counseling. PatientNotes captures the assessment as a structured paragraph that references the lab values it actually used, so the note is both auditable and useful at the next visit.
The encounter that benefits most is the new sickle cell consult or the new MPN workup - 60 minutes of dense history followed by a CBC and peripheral smear review and a long differential. Without ambient capture, those visits can take 75-90 minutes to write up. With it, the note is finalized before the next patient is roomed.
Sample AI-Generated Hematology Note
Routine 3-month apixaban follow-up for paroxysmal AFib. Shown verbatim - the only typical edits are tightening the assessment paragraph.
SUBJECTIVE: 72-year-old male with paroxysmal atrial fibrillation (CHA2DS2-VASc 4: HTN, DM, age >= 65, age >= 75 - so really 5 if recalculated; HAS-BLED 2) presents for routine 3-month anticoagulation follow-up. On apixaban 5mg PO BID since 2022. No bleeding events. No new TIA or stroke symptoms. No falls. Compliant with twice-daily dosing per pill organizer review. Reports stable AFib symptoms. Occasional palpitations 1-2x per month, lasting <15 minutes, self-resolving. No syncope. No dyspnea on exertion beyond baseline. Walks 30 minutes daily. No chest pain. Sleeps flat. No lower extremity swelling. Diet stable. Drinks 1-2 glasses of wine on weekends. No grapefruit. Has discussed apixaban-grapefruit interaction (no significant CYP3A4 effect with apixaban, mostly relevant for rivaroxaban/dabigatran - reassured patient). Other meds: Metoprolol succinate 50mg daily, lisinopril 20mg daily, atorvastatin 40mg daily, metformin 1000mg BID. No NSAIDs. No herbal supplements. ROS: Negative for melena, hematochezia, hematuria, epistaxis, easy bruising, gum bleeding, headache, focal weakness, vision change. OBJECTIVE: Vitals: BP 132/78, HR 72 regular, RR 14, Wt 84 kg, Temp 98.0F, SpO2 97% RA. General: Well-appearing male, no acute distress. HEENT: No conjunctival pallor, no oral mucosal bleeding, no petechiae. CV: Regular rate and rhythm today, no murmurs, no gallop, no rub. JVP not elevated. Pulm: Clear to auscultation bilaterally. Abdomen: Soft, non-tender, no hepatosplenomegaly, no masses. Extremities: No edema, no calf tenderness, no signs of bleeding or hematoma. Pulses 2+ throughout. Skin: No petechiae, no purpura, no ecchymoses. No injection site bleeding. Neuro: Alert and oriented x3, no focal deficits, gait steady, no past-pointing. Labs (today): - CBC: WBC 6.4 (normal differential), Hgb 13.6, Hct 41, Plt 218,000, MCV 88, RDW 12.8 (all normal). - BMP: Cr 1.1, eGFR 64 mL/min/1.73m2, K 4.2, Na 140, Glu 118. - LFTs: AST 22, ALT 24, Alb 4.2, Bili 0.7. - Apixaban level not routinely indicated; renal function adequate for standard dosing. CrCl by Cockcroft-Gault: ((140-72) x 84) / (72 x 1.1) = 72 mL/min. Adequate for apixaban 5mg BID standard dosing. Pill count today: 90 dispensed 90 days ago, 4 remaining (vs expected 0-2). Slight overage - patient confirms occasional missed dose, less than 1 per week. Adherence acceptable but reinforced. ASSESSMENT: 1. Paroxysmal atrial fibrillation on apixaban for stroke prevention (I48.0, Z79.01). - CHA2DS2-VASc 5 (age >= 75 contributes 2): ischemic stroke risk ~6.7% per year off anticoagulation. - HAS-BLED 2 (HTN, age >= 65): bleeding risk acceptable. - On apixaban 5mg BID - dosing appropriate (no dose-reduction criteria met: serum Cr 1.1 not >= 1.5, age 72 not >= 80, weight 84 kg not <= 60 kg - need 2 of 3 for 2.5mg BID). - No bleeding events, INR not applicable (DOAC). Therapy effective and well-tolerated. 2. Type 2 diabetes mellitus and hypertension - co-managed by primary care. 3. Mild renal insufficiency (eGFR 64) - stable, no apixaban dose adjustment needed. PLAN: 1. Continue apixaban 5mg PO BID. Verified no dose-reduction criteria. 2. Continue current rate-control with metoprolol succinate 50mg daily; rate-control adequate today. 3. Bridge plan documented for any future invasive procedure: hold apixaban 24-48 hours pre-procedure depending on bleeding risk, resume 24 hours after low-bleeding-risk procedures, 48-72 hours after high-bleeding-risk procedures. No bridging with LMWH for DOACs unless very high thrombotic risk (atrial thrombus, mechanical valve) - and this patient does not have those risk factors. 4. Pill organizer continues - reviewed adherence and reinforced importance of every-12-hour dosing. 5. CBC, BMP, LFTs in 6 months for renal/hepatic surveillance on apixaban. 6. Counseled on bleeding red flags: melena, hematochezia, hematuria, severe headache, sudden vision change, syncope, fall with head strike. Hold apixaban and call office or go to ED for any of these. 7. Influenza, COVID-19, and pneumococcal vaccines verified up-to-date. 8. Return in 6 months for routine follow-up; sooner for any bleeding, falls, planned procedure, or new symptoms. Billing: 99214. Moderate complexity - one chronic condition on a high-risk anticoagulant with labs and adherence reviewed, decision-making includes risk-benefit assessment of continuing therapy. ICD-10: I48.0 + Z79.01 + I10 + E11.9 + N18.2.
Most-Used ICD-10 Codes in Hematology
The system suggests these based on the assessment, with one-click selection.
D69.6Thrombocytopenia, unspecifiedD57.1Sickle-cell disease without crisisD57.00Hb-SS disease with crisis, unspecifiedD50.9Iron deficiency anemia, unspecifiedD63.0Anemia in neoplastic diseaseI48.0Paroxysmal atrial fibrillationI82.40Acute embolism and thrombosis of unspecified deep veins of lower extremityZ79.01Long term (current) use of anticoagulantsPair anticoagulation visits with Z79.01 (long-term anticoagulant use) plus the active indication (I48.0 AFib, I82.40 DVT, I26.99 PE).
How Hematologists Actually Use It
Three real-world deployments. Names anonymized; setting and outcome accurate.
Dr. A. Williams
Solo benign hematologist, anticoagulation clinic, Atlanta GA
Runs a high-volume warfarin and DOAC clinic with 22-26 patients per day, mostly Medicare-age AFib and post-VTE patients. Was using Dragon dictation but spending 90 minutes after clinic finishing notes. Switched to PatientNotes in early 2026 and now leaves at 5pm with notes done. Specifically values the INR-trend carry-forward and the HAS-BLED score auto-population.
Tidewater Sickle Cell Center
3-physician benign hematology practice, coastal Virginia
Specialty sickle cell clinic embedded in a community hospital. Group of three hematologists evaluated Abridge and PatientNotes during a Q4 2025 vendor review. Picked PatientNotes for two reasons: (1) the per-seat cost was ~$150/month vs ~$900/month for Abridge enterprise pricing, and (2) the ability to capture hydroxyurea titration, HbF response, and crisis frequency in a structured visit-over-visit format mattered for their NIH-funded outcomes registry submissions.
Dr. S. Park
Hospital-employed BMT physician, academic medical center
Works in a large academic stem-cell transplant program with Epic. Hospital provides Abridge through the enterprise contract for inpatient consults. Uses personal PatientNotes subscription for the post-transplant outpatient follow-up clinic because the structured GVHD grading capture and the cleaner consult-letter format are better suited to the long-term BMT survivorship workflow. Pastes the structured note into Epic as a SmartPhrase.
Coming from Microsoft Dragon?
Many hematologists trained over the past 15 years dictate fluently into Dragon. Here is the honest comparison.
Dragon Medical One (DMO) is a dictation engine: it converts speech to text after the patient leaves. It is mature, well-engineered, and has the largest installed base of any clinical voice product. Many hematologists have macros and SmartPhrases for warfarin INR clinic, sickle cell crisis, and BM biopsy procedure notes that took years to refine - that is real value and a real switching cost.
The functional difference is between dictation and ambient capture. Dragon converts spoken text after the visit; PatientNotes listens to the entire encounter and structures the note from the conversation itself. For a busy hematologist, the time savings come from never composing the note - not from typing or dictating faster.
Dragon Medical One
- $99/month + setup fee
- Dictation, not ambient
- Mature Epic and Cerner integration
- You compose the note out loud
- Strong macro and SmartPhrase ecosystem
PatientNotes
- $50/month, all-in
- Ambient capture
- Browser- and iOS-based, paste into any EHR
- Note composed from the conversation
- Hematology templates included out of the box
How to switch in three steps
- Run a 7-day free trial in parallel with Dragon. Pick a single anticoagulation- or sickle-cell-clinic day - record three or four visits and paste the generated note next to the one you dictated.
- Compare on three axes: completeness of the CBC interpretation, accuracy of the INR/DOAC dose capture, and minutes of after-clinic editing.
- If PatientNotes wins, schedule the Dragon cancellation for the next renewal date. Both keep working in parallel until the renewal, so there is no documentation gap.
Is Abridge Better than PatientNotes for Hematology?
Honest comparison vs the most-cited specialty competitor.
Abridge (abridge.com) is the AI scribe most-frequently named in oncology and hematology vendor reviews. It is well-engineered, has invested heavily in clinical evidence (Brigham, UPMC publications), and has deep Epic integration through the App Orchard, including FHIR-based note write-back. For a large enterprise health system already standardized on Epic, those integrations carry real weight.
The honest tradeoff is on price and accessibility. Abridge publishes only enterprise pricing and is typically deployed at $250-$400/month per clinician through hospital contracts. The implementation cycle is 60-90 days and requires Epic IT involvement. PatientNotes is $50/month all-in, browser- and iOS-based, deploys in five minutes, and produces structurally similar hematology output - anticoagulation visit, sickle cell follow-up, anemia workup, BMT survivorship.
The honest verdict: if your hospital pays for Abridge through the enterprise contract, use it - it is a good tool. If you are an independent benign hematologist, a small hem/onc group, or a hospital-employed hematologist who wants supplemental coverage outside the enterprise tool, PatientNotes is the better economic choice with output that is hard to tell apart in a blinded comparison.
Frequently Asked Questions
Last updated April 2026 by the PatientNotes Clinical Team.
Does PatientNotes work for hematology?
Yes. It is used by benign and malignant hematologists for anticoagulation management, sickle cell clinic, anemia workup, bleeding disorders (von Willebrand, hemophilia, ITP), hereditary conditions (thalassemia, hereditary spherocytosis, G6PD), and post-BMT follow-up. The system interprets CBC differentials by morphology, trends INR, captures hydroxyurea titration, and tags BM biopsy procedure codes (38220, 38221).
How much does an AI scribe cost for hematology?
PatientNotes is $50/month per clinician on an annual plan, with unlimited visits. Abridge publishes enterprise pricing only and typically deploys at $250-$400/month per clinician through hospital contracts. DeepScribe runs $200-$400/month per seat list. For a hematology group of three clinicians, PatientNotes works out to roughly $1,800/year vs $9,000-$14,400/year for Abridge.
Is Abridge better than PatientNotes for hematology?
Abridge is excellent inside enterprise Epic deployments where its FHIR-based note write-back and clinical evidence carry weight. It is also five-to-eight times more expensive at list and sells primarily through hospital contracts. PatientNotes produces structurally similar output and deploys in five minutes. If your hospital pays for Abridge, use it; if you are paying out of pocket, PatientNotes is the better value.
Can hematology-specific notes be auto-generated?
Yes. Templates ship for anticoagulation management (warfarin/DOAC, INR trend, HAS-BLED, indication review), sickle cell visit (crisis history, hydroxyurea, transfusion needs), anemia workup, bleeding disorders, hereditary hematologic conditions, and BMT follow-up (engraftment, GVHD, prophylaxis, immunosuppression taper). Custom templates are also supported for sub-specialty workflows.
Does it integrate with Epic, Cerner, or hematology-specific EHRs?
PatientNotes generates a finished note that you paste into any EHR - Epic, Cerner PowerChart, OncoEMR by Elekta, Athenahealth, NextGen, eClinicalWorks. There is no FHIR install required. A direct Epic write-back through the App Orchard is on the 2026 roadmap.
Will it help me bill hematology CPT codes correctly?
The system documents the elements driving outpatient E&M level under 2021 AMA guidelines (problems, data reviewed, risk). Procedure codes the system tags include BM aspiration only (38220), BM biopsy with aspiration (38221), therapeutic phlebotomy (99195), and iron sucrose infusion (J1756 with 96365). Final code selection still belongs to your biller.
How do I switch from Dragon Medical One to PatientNotes?
Three steps. Run a 7-day free trial in parallel with Dragon for one anticoagulation or sickle cell clinic day, compare on completeness and editing time, and if PatientNotes wins, schedule Dragon cancellation for the next renewal. Both keep working until then, no documentation gap. Most hematologists who switch report 60-90 minutes per day saved.
Is it HIPAA compliant for hematology?
Yes. PatientNotes operates under a Business Associate Agreement, encrypts audio and text in transit (TLS 1.3) and at rest (AES-256), and stores data in US-based AWS regions. Audio is deleted after transcription unless retention is opted in. SOC 2 Type II is in progress. The BAA is signed during onboarding and applies to academic, community, and telehealth hematology practices.
Related resources
- AI scribe for oncology - for combined hem/onc practices
- AI scribe for internal medicine - for hematologists who maintain hospitalist coverage
- PatientNotes vs Abridge
- Full pricing breakdown
Leave clinic with notes done.
Hematologists running PatientNotes typically reclaim 60-90 minutes per clinic day. Seven-day free trial, no card required, cancel any time.
No credit card required. $50/month after trial.